Trending...
- Cybersecurity is Protecting Your Personal Information and Your Portfolio
- State Launches Colorado Property Tax Map as a Central Source to Understand Taxing Jurisdictions and Property Tax Rates
- $56.7 Million Announced in Q1 2025 with Revenue Growth and Progress Toward NASDAQ Uplisting for AI Marketing Company: IQSTEL, Inc. Stock Symbol: IQSTD
Eve Wellness located in SF offers the first FDA-approved ultrasound screening technology specifically designed for detecting cancer in dense breast tissue.
SAN FRANCISCO - ColoradoDesk -- Eve Wellness, a San Francisco-based breast cancer screening clinic, is leading the charge in breast cancer screening by providing women the opportunity to get screened earlier, at any age, without a doctor referral, using their FDA-Approved GE ABUS ultrasound technology, powered by FDA-Approved AI (artificial intelligence), all without radiation. This comes on the heels of the FDA's new mandate, announced on March 9, 2023, requiring all mammography facilities to report breast density information and enhance communications with patients and providers.
The FDA's move is important because the risk of breast cancer is of real concern to many patients, said Dr. Harold Burstein, a medical oncologist at the Dana-Farber Cancer Institute in Boston and a professor at Harvard Medical School. "The identification of dense breast tissue can be a marker of slightly greater risk of getting breast cancer, and it may need additional breast imaging," said Burstein, who likened the challenge of reading mammograms to "looking through frosted glass."
More on Colorado Desk
Breast density has been identified as a risk factor for breast cancer, and the FDA's new mandate aims to increase awareness and understanding of this risk. The mandate requires mammography facilities to provide patients with information about their breast density and the impact it can have on the accuracy of mammograms. Facilities are also required to communicate the findings with healthcare providers and provide recommendations for additional screening options, such as breast ultrasound.
"Today's action represents the agency's broader commitment to support innovation to prevent, detect and treat cancer," said Hilary Marston, M.D., M.P.H., FDA's Chief Medical Officer. "Since 1992, the FDA has worked to ensure patients have access to quality mammography. The impact of the Mammography Quality Standards Act on public health has been significant, including a steep decrease in the number of facilities that do not meet quality standards. This means that more women have access to consistent, quality mammography. We remain committed to advancing efforts to improve the health of women and strengthen the fight against breast cancer."
At Eve Wellness, breast ultrasound is the best option for women with dense breast tissue. Their GE ABUS ultrasound technology, powered by AI, can detect breast cancer at an earlier stage and without the use of radiation. With physician-read results back in less than 48 hours, Eve Wellness provides women with quick results, reducing anxiety and enabling early intervention.
More on Colorado Desk
"Breast cancer claims the lives of nearly 43,000 women annually, and early detection is key to improving outcomes. Eve is on a mission to fill the void in breast cancer screening," said Brendan Foley, Co-Founder at Eve Wellness. "We are proud to lead the change in breast screening by providing women with access to the latest technology and empowering them to take control of their breast health."
Eve Wellness is committed to providing women with the best possible breast cancer screening options and is a game-changer in the fight against breast cancer. With the FDA's new mandate, women can feel more informed and empowered in their breast health decisions, and Eve Wellness is here to support them every step of the way.
For more information on Eve Wellness and their breast cancer screening services, visit their website at https://www.myevewellness.com/.
The FDA's move is important because the risk of breast cancer is of real concern to many patients, said Dr. Harold Burstein, a medical oncologist at the Dana-Farber Cancer Institute in Boston and a professor at Harvard Medical School. "The identification of dense breast tissue can be a marker of slightly greater risk of getting breast cancer, and it may need additional breast imaging," said Burstein, who likened the challenge of reading mammograms to "looking through frosted glass."
More on Colorado Desk
- Colorado Springs Fire Department 2025 Living with Wildfire Town Hall
- Colorado: Governor Polis Signs Construction Defects Law, Ending Years of Gridlock to Build Housing People Can Afford
- Mother's Day Wake-Up Call for Maternal Health: New Initiative Demands Better Postpartum Support
- Southbox Entertainment, FinTech Pioneer & Entrepreneur Jon Gosier Join Psychological Thriller The Dutchman as Financing Partner
- SlotCycle Joins Association of Gaming Equipment Manufacturers (AGEM) to Advance Sustainable Gaming Solutions
Breast density has been identified as a risk factor for breast cancer, and the FDA's new mandate aims to increase awareness and understanding of this risk. The mandate requires mammography facilities to provide patients with information about their breast density and the impact it can have on the accuracy of mammograms. Facilities are also required to communicate the findings with healthcare providers and provide recommendations for additional screening options, such as breast ultrasound.
"Today's action represents the agency's broader commitment to support innovation to prevent, detect and treat cancer," said Hilary Marston, M.D., M.P.H., FDA's Chief Medical Officer. "Since 1992, the FDA has worked to ensure patients have access to quality mammography. The impact of the Mammography Quality Standards Act on public health has been significant, including a steep decrease in the number of facilities that do not meet quality standards. This means that more women have access to consistent, quality mammography. We remain committed to advancing efforts to improve the health of women and strengthen the fight against breast cancer."
At Eve Wellness, breast ultrasound is the best option for women with dense breast tissue. Their GE ABUS ultrasound technology, powered by AI, can detect breast cancer at an earlier stage and without the use of radiation. With physician-read results back in less than 48 hours, Eve Wellness provides women with quick results, reducing anxiety and enabling early intervention.
More on Colorado Desk
- Colorado Springs: Podcast: Police Appreciation Week
- RWA Infra Development L.L.C. announces the $RWAID token. "$RWAID tokenizing infrastructure for the masses."
- Mental Health Awareness Month—Tennessee Enacts Psychotropic Testing Law
- Be Prepared for the Qualitative and Quantitative Effects of Tariffs: How Businesses Can Navigate Potential Disruption in Finances and Production
- Bold Beauty Project UCLA Edition Photography Exhibition on May 18
"Breast cancer claims the lives of nearly 43,000 women annually, and early detection is key to improving outcomes. Eve is on a mission to fill the void in breast cancer screening," said Brendan Foley, Co-Founder at Eve Wellness. "We are proud to lead the change in breast screening by providing women with access to the latest technology and empowering them to take control of their breast health."
Eve Wellness is committed to providing women with the best possible breast cancer screening options and is a game-changer in the fight against breast cancer. With the FDA's new mandate, women can feel more informed and empowered in their breast health decisions, and Eve Wellness is here to support them every step of the way.
For more information on Eve Wellness and their breast cancer screening services, visit their website at https://www.myevewellness.com/.
Source: Eve Wellness, Inc.
Filed Under: Health
0 Comments
Latest on Colorado Desk
- Aureli Construction Sets the Standard for Seamless Home Additions in Greater Boston
- Colorado Springs: Jessie Kimber inducted as Fort Carson Good Neighbor
- ScreenPoints Puts Film Investors in the Credits—and in the Money With New FinTech Platform
- Pathways to Adulthood Conference May 17 at Melville Marriott Honoring NYS Assembly Member Jodi Giglio, Suffolk County Legislator Nick Caracappa
- Adster Techologies awarded US Patent for breakthrough innovation in reducing latency in Ad Serving
- Colorado: Governor Polis: Real Results Delivered for Coloradans in 2025 Legislative Session
- Robert Fabbio Inducted into the Austin Technology Council Hall of Fame
- Need a Rental Venue? Evergood Wines Hosts Parties, Reunions, and Nonprofits on Its Outdoor Patio
- Poor Richard's Celebrates 50 Years of Community, Culture, and Connection
- Colorado: Governor Polis Appoints Michal A. Lord-Blegen to the 17th Judicial District Court
- Colorado Springs: Mayor Yemi, City Councilmembers to host 2025 Report Out Community Tour
- Cybersecurity is Protecting Your Personal Information and Your Portfolio
- Master Local Search Engine Optimization: BSM Hosts Free Webinar Featuring SE Ranking
- Colorado is REAL ID Ready
- Colorado: Proposition 123 Land Banking Funds to Support New Housing Options Coloradans can Afford Across the State
- L2 Aviation Celebrates Grand Opening of New Facility at Cincinnati/Northern Kentucky International Airport (CVG)
- Managing Summer Staffing Surges with Confidence: Why Name Badges Are a Must for Seasonal Success
- Visa Named Title Sponsor of Ascending Athletes' Business Owners Summits for NFL Entrepreneurs
- The Paris Court of International Arbitration Elects Dr. John J. Maalouf as its New President
- $56.7 Million Announced in Q1 2025 with Revenue Growth and Progress Toward NASDAQ Uplisting for AI Marketing Company: IQSTEL, Inc. Stock Symbol: IQSTD